Brief: CASI Pharmaceuticals Partner, Bioinvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients

BioInvent International AB

28/01/2021 12:23

Jan 28 (Reuters) - BioInvent International AB  BINV.ST :
    * CASI PHARMACEUTICALS PARTNER, BIOINVENT, PRESENTS PHASE
I/IIA
DATA THAT SUGGESTS BI-1206 RESTORES ACTIVITY OF RITUXIMAB IN
RELAPSED NON-HODGKIN'S LYMPHOMA PATIENTS

Source text for Eikon:  ID:nPn7l5zMma 
Further company coverage:  BINV.ST 

 ((Reuters.Briefs@thomsonreuters.com;))